Cyrille Hulin

Summary

Affiliation: CHU de Nancy
Country: France

Publications

  1. doi request reprint Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    Cyrille Hulin
    Service d Hematologie, rue du Morvan, Centre Hospitalier Universitaire de Nancy Brabois, 54511 Vandoeuvre, France
    J Clin Oncol 27:3664-70. 2009
  2. ncbi request reprint [New treatment of multiple myeloma]
    C Hulin
    Service d hématologie et de médecine interne, CHU de Nancy, Hopitaux de Brabois, rue du Morvan, 54511 Vandoeuvre, France
    Rev Med Interne 28:682-8. 2007
  3. ncbi request reprint Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Thierry Facon
    Service d Hematologie, Centre Hospitalier Universitaire, Lille, France
    Lancet 370:1209-18. 2007
  4. ncbi request reprint Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    Michel Attal
    Service d Hematologie, Hopital Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Blood 108:3289-94. 2006
  5. ncbi request reprint Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells
    Pierre Feugier
    Department of Hematology, University Hospital, Nancy, France
    Transfusion 43:878-84. 2003
  6. ncbi request reprint [Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia]
    S Leonard
    Service de Neurologie, Hopital Central, CHU de Nancy, France
    Rev Neurol (Paris) 158:1121-3. 2002
  7. doi request reprint Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
  8. doi request reprint Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Pieter Sonneveld
    Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands
    Cancer 112:1529-37. 2008
  9. ncbi request reprint Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
    P Moreau
    Hematology Department, University Hospital, Nantes, France
    Leukemia 21:2020-4. 2007
  10. ncbi request reprint [Granulocyte sarcoma of the pancreas without extra-pancreatic location]
    S Dimicoli
    Service d hématologie et de médecine interne, CHU Nancy Brabois, Allee du Morvan, 54511 Vandoeuvre
    Presse Med 31:1024-6. 2002

Collaborators

Detail Information

Publications10

  1. doi request reprint Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    Cyrille Hulin
    Service d Hematologie, rue du Morvan, Centre Hospitalier Universitaire de Nancy Brabois, 54511 Vandoeuvre, France
    J Clin Oncol 27:3664-70. 2009
    ..This randomized, placebo-controlled, phase III trial investigated the efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed myeloma...
  2. ncbi request reprint [New treatment of multiple myeloma]
    C Hulin
    Service d hématologie et de médecine interne, CHU de Nancy, Hopitaux de Brabois, rue du Morvan, 54511 Vandoeuvre, France
    Rev Med Interne 28:682-8. 2007
    ....
  3. ncbi request reprint Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Thierry Facon
    Service d Hematologie, Centre Hospitalier Universitaire, Lille, France
    Lancet 370:1209-18. 2007
    ..We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival...
  4. ncbi request reprint Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    Michel Attal
    Service d Hematologie, Hopital Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Blood 108:3289-94. 2006
    ..4). Thalidomide is an effective maintenance therapy in patients with multiple myeloma. Maintenance treatment with pamidronate does not decrease the incidence of bone events...
  5. ncbi request reprint Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells
    Pierre Feugier
    Department of Hematology, University Hospital, Nancy, France
    Transfusion 43:878-84. 2003
    ..It is not clear whether the quantification of CFU-GM and CD34+ cells should be done on fresh components and after cryopreservation, which better represents the actual composition of the graft...
  6. ncbi request reprint [Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia]
    S Leonard
    Service de Neurologie, Hopital Central, CHU de Nancy, France
    Rev Neurol (Paris) 158:1121-3. 2002
    ..The presence of JC virus was demonstrated first by in situ hybridation after a brain biopsy and second with polymerase chain reaction on CSF. The diagnosis of PML was confirmed. The causality of fludarabine treatment is discussed...
  7. doi request reprint Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
    ..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy...
  8. doi request reprint Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Pieter Sonneveld
    Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands
    Cancer 112:1529-37. 2008
    ....
  9. ncbi request reprint Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
    P Moreau
    Hematology Department, University Hospital, Nantes, France
    Leukemia 21:2020-4. 2007
    ..The achievement of either complete response or very good partial response after HDT was also a powerful independent prognostic factor for both OS and EFS...
  10. ncbi request reprint [Granulocyte sarcoma of the pancreas without extra-pancreatic location]
    S Dimicoli
    Service d hématologie et de médecine interne, CHU Nancy Brabois, Allee du Morvan, 54511 Vandoeuvre
    Presse Med 31:1024-6. 2002
    ..The pancreatic location and recurrence, aside from any context of malignant hemopathy, are exceptional...